XM does not provide services to residents of the United States of America.
A
A

Abbott

News

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott’S Freestyle Libre 2 Plus Sensor In The US

BRIEF-Insulet Announces Omnipod 5 System Is Now Compatible With Abbott’S Freestyle Libre 2 Plus Sensor In The US Nov 20 (Reuters) - Abbott Laboratories ABT.N : INSULET ANNOUNCES OMNIPOD® 5 SYSTEM IS NOW COMPATIBLE WITH ABBOTT’S FREESTYLE LIBRE 2 PLUS SENSOR IN THE U.S. Source text: ID:nBw49Vv3la Further company coverage: ABT.N
A

UK regulator flags concerns and remedies for sale of baby formula

UPDATE 1-UK regulator flags concerns and remedies for sale of baby formula Adds details throughout Nov 8 (Reuters) - Britain's competition watchdog flagged concerns and potential solutions regarding the distribution of infant formulas on Friday, which could help improve the sector as well as reduce costs for parents. The Competition and Markets Authority's (CMA) initial recommendations include providing parents clear and accurate information on the nutritional value of the formula and standardis
A

UK's CMA Flags Concerns And Remedies For Sale Of Baby Formula

BRIEF-UK's CMA Flags Concerns And Remedies For Sale Of Baby Formula Nov 8 (Reuters) - UK's CMA: INFANT FORMULA: CMA SETS OUT CONCERNS & SOLUTIONS CONCERNS REGARDING INFANT FORMULA MARKET - ALL OF WHICH APPEAR TO BE CONTRIBUTING TO PARENTS PAYING OVER ODDS SETTING OUT A NUMBER OF POTENTIAL OPTIONS THAT COULD HELP IMPROVE SECTOR AND REDUCE COSTS FOR PARENTS POTENTIAL OPTIONS INCLUDE PROVIDING CLEAR, ACCURATE, AND IMPARTIAL INFORMATION POTENTIAL OPTIONS INCLUDE STRENGTHENING LABELLING AND ADVERTISI
A

UK regulator flags concerns and remedies for sale of baby formula

UK regulator flags concerns and remedies for sale of baby formula Nov 8 (Reuters) - Britain's competition watchdog flagged concerns and potential solutions regarding the distribution of infant formulas on Friday, which could help improve the sector as well as manage costs for parents. Reporting by Yamini Kalia in Bengaluru; Editing by Rashmi Aich
A

Becton Dickinson beats quarterly estimates on strength in drug-delivery devices

Becton Dickinson beats quarterly estimates on strength in drug-delivery devices Nov 7 (Reuters) - Becton Dickinson BDX.N surpassed analysts' expectations for fourth-quarter results on Thursday, helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N have been benefiting from robust demand for non-essential surgical procedures, especially among older patients.
A
B

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.